A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.
XOMA to buy Kinnate; A pain biotech’s small IPO
Plus, news about Blueprint Medicines, Sosei Group and Poxel: XOMA to buy Kinnate Biopharma: The biotech royalty aggregator said it would pay $2.33 per share